Iclusig (ponatinib) — United Healthcare
Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Initial criteria
- Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Iclusig therapy
Approval duration
12 months